Sarepta Therapeutics Inc. has a chance to shake off a summer slump -- which cut shares in half from a July peak and wiped out $6 billion in market value -- when the drugmaker presents early results from its experimental gene therapy.

Sarepta Therapeutics Inc.’s bulls may get some validation after the company’s experimental gene therapy for a rare type of muscular dystrophy improved physical fitness in a trio of patients.

NEW YORK (Reuters) - A CVS Health Corp CVS.N health plan that uses an outside drug pricing group to help it decide whether to cover certain new medicines has gained little traction with customers, according to its top medical executive, and has drawn fierce criticism from patient advocacy groups.

TOKYO (Reuters) - Japan's "overly restrictive" drug pricing policies risk diverting foreign direct investment to China and other markets, the chief executive of Bristol-Myers Squibb said on Thursday.

Jeremy Corbyn took to the podium at this year’s Labour party conference to reveal his bold new “Medicines for the Many” initiative. In his speech, he accused the pharmaceutical industry of profiteering and suggested that patients were “being denied lifesaving medicines by a system that puts profits for shareholders before…

Executive order planned for Thursday will focus on modernizing Medicare by increasing access to telehealth and innovative therapies.